Tempus AI, Inc. (NASDAQ:TEM) Receives $48.67 Consensus Target Price from Analysts

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $48.67.

A number of brokerages recently issued reports on TEM. William Blair began coverage on Tempus AI in a research report on Tuesday, July 9th. They set an “outperform” rating for the company. Morgan Stanley initiated coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set an “overweight” rating and a $44.00 price target for the company. TD Cowen initiated coverage on shares of Tempus AI in a report on Tuesday, July 9th. They issued a “buy” rating and a $50.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $47.00 target price on shares of Tempus AI in a report on Wednesday, August 7th. Finally, Longbow Research assumed coverage on Tempus AI in a research report on Tuesday, July 9th. They issued a “buy” rating and a $48.00 target price on the stock.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $49.34 on Thursday. The company has a debt-to-equity ratio of 4.50, a current ratio of 3.70 and a quick ratio of 3.52. The business’s 50 day moving average price is $52.38. Tempus AI has a 1 year low of $22.89 and a 1 year high of $77.00.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, August 6th. The company reported ($6.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.41) by ($2.36). The business had revenue of $165.97 million during the quarter, compared to the consensus estimate of $159.10 million. On average, analysts anticipate that Tempus AI will post -6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently modified their holdings of TEM. Davidson Kempner Capital Management LP purchased a new position in Tempus AI in the second quarter valued at $2,271,000. NEA Management Company LLC acquired a new stake in Tempus AI in the 2nd quarter valued at about $160,048,000. Exchange Traded Concepts LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $3,458,000. Sculptor Capital LP acquired a new position in shares of Tempus AI during the second quarter worth about $5,085,000. Finally, Novo Holdings A S purchased a new stake in shares of Tempus AI during the second quarter worth approximately $142,605,000.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.